47 related articles for article (PubMed ID: 7998098)
1. Toxicity of IgA anti-CD3 isotype switch variant in vivo.
ten Berge IJ; Parlevliet KJ; Yong SL; Surachno J; Wilmink JM; Schellekens PT
Transplant Proc; 1994 Dec; 26(6):3150. PubMed ID: 7998098
[No Abstract] [Full Text] [Related]
2. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.
Parlevliet KJ; ten Berge IJ; Yong SL; Surachno J; Wilmink JM; Schellekens PT
J Clin Invest; 1994 Jun; 93(6):2519-25. PubMed ID: 8200988
[TBL] [Abstract][Full Text] [Related]
3. A rat anti-mouse CD3 monoclonal antibody induces long-term skin allograft survival without inducing side effects.
Vossen AC; Tibbe GJ; van Oudenaren A; Vredendaal AE; Benner R; Savelkoul HF
Transplant Proc; 1994 Dec; 26(6):3157-8. PubMed ID: 7998101
[No Abstract] [Full Text] [Related]
4. [Salvage therapy with anti-IL-2 receptor antibodies in high-risk kidney transplant patients].
Carl S; Wiesel M; Deiss JM; Daniel V; Opelz G; Staehler G
J Urol (Paris); 1997; 103(1-2):7-9. PubMed ID: 9765770
[No Abstract] [Full Text] [Related]
5. Involvement of tumor necrosis factor in development of anti-CD3 monoclonal antibody induced pulmonary edema.
Nakajima F; Nakamura H; Stenzel KH; Suthanthiran M
Transplant Proc; 1994 Aug; 26(4):1939-40. PubMed ID: 8066628
[No Abstract] [Full Text] [Related]
6. Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial.
Friend PJ; Calne RY; Hale G; Waldmann H; Evans DB; Rolles K; Thiru S; Gore S
Transplant Proc; 1987 Feb; 19(1 Pt 3):1898-900. PubMed ID: 3079058
[No Abstract] [Full Text] [Related]
7. Monoclonal antibody-mediated toxicity in Cryptococcus neoformans infection: mechanism and relationship to antibody isotype.
Lendvai N; Casadevall A
J Infect Dis; 1999 Sep; 180(3):791-801. PubMed ID: 10438368
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of isotype on efficacy of anti-tumor necrosis factor alpha chimeric antibodies in experimental septic shock.
Suitters AJ; Foulkes R; Opal SM; Palardy JE; Emtage JS; Rolfe M; Stephens S; Morgan A; Holt AR; Chaplin LC
J Exp Med; 1994 Mar; 179(3):849-56. PubMed ID: 8113678
[TBL] [Abstract][Full Text] [Related]
9. The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.
ter Meulen CG; Jacobs CW; Wetzels JF; Klasen IS; Hilbrands LB; Hoitsma AJ
Transplantation; 2004 Jan; 77(2):281-6. PubMed ID: 14742994
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic OKT3: practical considerations for the prevention of first-dose reactions.
Doutrelepont JM; Abramowicz D; Borre B; Lemoine A; De Pauw L; Kinnaert P; Vereerstraeten P; Vanherweghem JL; Goldman M
Transplant Proc; 1993 Apr; 25(2 Suppl 1):45-6. PubMed ID: 8465424
[No Abstract] [Full Text] [Related]
11. Cytokine secretion capacity of mononuclear cells in renal transplant recipients: the effect of two different dose schedules.
Leimenstoll G; Engemann R; Gassel J; Hoffmann S; Preusse D; Schlag H; Niedermayer W
Transplant Proc; 1993 Aug; 25(4):2666-8. PubMed ID: 8356715
[No Abstract] [Full Text] [Related]
12. A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody.
Renkl A; Mockenhaupt M; Technau K; Herouy Y; Norgauer J
Br J Dermatol; 2004 Jun; 150(6):1220-2. PubMed ID: 15214921
[No Abstract] [Full Text] [Related]
13. In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice. Effects of pentoxifylline, methylprednisolone, anti-TNF, and anti-IFN-gamma antibodies.
Bemelmans MH; Abramowicz D; Gouma DJ; Goldman M; Buurman WA
J Immunol; 1994 Jul; 153(2):499-506. PubMed ID: 8021491
[TBL] [Abstract][Full Text] [Related]
14. Counting of lymphocyte subpopulations using standard versus low-dose antiCD3 monoclonal antibody treatment.
González-Martínez F; Curi L; Núñez H; González AC; Orihuela N; González G; Orihuela S
Transplant Proc; 2004; 36(6):1659-60. PubMed ID: 15350443
[TBL] [Abstract][Full Text] [Related]
15. Pentoxifylline reduces the first-dose reactions following OKT3.
Vincenti FG; Vasconcelos M; Birnbaum JL; Tomlanovich SJ; Amend WJ; Melzer JS; Snyder JP
Transplant Proc; 1993 Apr; 25(2 Suppl 1):57-9. PubMed ID: 8465428
[No Abstract] [Full Text] [Related]
16. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates.
Arnold ML; Dechant M; Doxiadis II; Spriewald BM
Tissue Antigens; 2008 Jul; 72(1):60-6. PubMed ID: 18588575
[TBL] [Abstract][Full Text] [Related]
18. Soluble tumour necrosis factor receptor release after anti-CD3 monoclonal antibody treatment in mice is independent of tumour necrosis factor-alpha release.
Vossen AC; Tibbe GJ; Buurman WA; Benner R; Savelkoul HF
Eur Cytokine Netw; 1996 Dec; 7(4):751-5. PubMed ID: 9010677
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin 2 monoclonal antibody following simultaneous pancreatic and kidney transplantation: a randomized trial vs rabbit antithymocyte globulin.
Cantarovich D; Hourmant M; Dantal J; Baatard R; Le Mauff B; Jacques Y; Paineau J; Murat A; Soulillou JP
Transplant Proc; 1993 Feb; 25(1 Pt 2):1366. PubMed ID: 8442143
[No Abstract] [Full Text] [Related]
20. Isotype selection for antibody-based cancer therapy.
Vukovic N; van Elsas A; Verbeek JS; Zaiss DMW
Clin Exp Immunol; 2021 Mar; 203(3):351-365. PubMed ID: 33155272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
